These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

555 related items for PubMed ID: 31654487

  • 1. Safety, Tolerability, Pharmacokinetics, Target Occupancy, and Concentration-QT Analysis of the Novel BTK Inhibitor Evobrutinib in Healthy Volunteers.
    Becker A, Martin EC, Mitchell DY, Grenningloh R, Bender AT, Laurent J, Mackenzie H, Johne A.
    Clin Transl Sci; 2020 Mar; 13(2):325-336. PubMed ID: 31654487
    [Abstract] [Full Text] [Related]

  • 2. No QTc Prolongation With Zanubrutinib: Results of Concentration-QTc Analysis From a Thorough QT Study in Healthy Subjects.
    Mu S, Darpo B, Tang Z, Novotny W, Tawashi M, Xue H, Willett M, Lin L, Sahasranaman S, Ou YC.
    Clin Transl Sci; 2020 Sep; 13(5):923-931. PubMed ID: 32144955
    [Abstract] [Full Text] [Related]

  • 3. Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis.
    Montalban X, Arnold DL, Weber MS, Staikov I, Piasecka-Stryczynska K, Willmer J, Martin EC, Dangond F, Syed S, Wolinsky JS, Evobrutinib Phase 2 Study Group.
    N Engl J Med; 2019 Jun 20; 380(25):2406-2417. PubMed ID: 31075187
    [Abstract] [Full Text] [Related]

  • 4. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single-Dose and Multiple-Rising-Dose Study of the BTK Inhibitor TAK-020 in Healthy Subjects.
    Esfandiari E, Chen M, Smithson G, Blair D, Faessel H, Wagner J, Mclean L, Fedyk ER.
    Clin Transl Sci; 2021 May 20; 14(3):820-828. PubMed ID: 33650758
    [Abstract] [Full Text] [Related]

  • 5. A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers.
    Smith PF, Krishnarajah J, Nunn PA, Hill RJ, Karr D, Tam D, Masjedizadeh M, Funk JO, Gourlay SG.
    Br J Clin Pharmacol; 2017 Nov 20; 83(11):2367-2376. PubMed ID: 28636208
    [Abstract] [Full Text] [Related]

  • 6. Safety, pharmacokinetics and pharmacodynamics of branebrutinib (BMS-986195), a covalent, irreversible inhibitor of Bruton's tyrosine kinase: Randomised phase I, placebo-controlled trial in healthy participants.
    Catlett IM, Nowak M, Kundu S, Zheng N, Liu A, He B, Girgis IG, Grasela DM.
    Br J Clin Pharmacol; 2020 Sep 20; 86(9):1849-1859. PubMed ID: 32198939
    [Abstract] [Full Text] [Related]

  • 7. Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Volunteers Treated With GDC-0853, a Selective Reversible Bruton's Tyrosine Kinase Inhibitor.
    Herman AE, Chinn LW, Kotwal SG, Murray ER, Zhao R, Florero M, Lin A, Moein A, Wang R, Bremer M, Kokubu S, Serone AP, Hanze EL, Viberg A, Morimoto AM, Winter HR, Katsumoto TR.
    Clin Pharmacol Ther; 2018 Jun 20; 103(6):1020-1028. PubMed ID: 29484638
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models.
    Haselmayer P, Camps M, Liu-Bujalski L, Nguyen N, Morandi F, Head J, O'Mahony A, Zimmerli SC, Bruns L, Bender AT, Schroeder P, Grenningloh R.
    J Immunol; 2019 May 15; 202(10):2888-2906. PubMed ID: 30988116
    [Abstract] [Full Text] [Related]

  • 9. Lack of effect of perampanel on QT interval duration: Results from a thorough QT analysis and pooled partial seizure Phase III clinical trials.
    Yang H, Laurenza A, Williams B, Patten A, Hussein Z, Ferry J.
    Epilepsy Res; 2015 Aug 15; 114():122-30. PubMed ID: 26088895
    [Abstract] [Full Text] [Related]

  • 10. Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases.
    Caldwell RD, Qiu H, Askew BC, Bender AT, Brugger N, Camps M, Dhanabal M, Dutt V, Eichhorn T, Gardberg AS, Goutopoulos A, Grenningloh R, Head J, Healey B, Hodous BL, Huck BR, Johnson TL, Jones C, Jones RC, Mochalkin I, Morandi F, Nguyen N, Meyring M, Potnick JR, Santos DC, Schmidt R, Sherer B, Shutes A, Urbahns K, Follis AV, Wegener AA, Zimmerli SC, Liu-Bujalski L.
    J Med Chem; 2019 Sep 12; 62(17):7643-7655. PubMed ID: 31368705
    [Abstract] [Full Text] [Related]

  • 11. A Phase 1 First-in-Human Pharmacokinetic and Pharmacodynamic Study of JNJ-64264681, a Covalent Inhibitor of Bruton's Tyrosine Kinase.
    Leu JH, Miao X, Shalayda K, Coe KJ, Kahnt A, Wu B, Schnarr M, Franks C, Devlin J, Yang TY, Palmer JA, Zhang M, Zhou H, Van Damme W, Smets S, Aguilar Z, Chaplan SR.
    Clin Pharmacol Drug Dev; 2023 Jun 12; 12(6):611-624. PubMed ID: 37125450
    [Abstract] [Full Text] [Related]

  • 12. Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials.
    Montalban X, Vermersch P, Arnold DL, Bar-Or A, Cree BAC, Cross AH, Kubala Havrdova E, Kappos L, Stuve O, Wiendl H, Wolinsky JS, Dahlke F, Le Bolay C, Shen Loo L, Gopalakrishnan S, Hyvert Y, Javor A, Guehring H, Tenenbaum N, Tomic D, evolutionRMS investigators.
    Lancet Neurol; 2024 Nov 12; 23(11):1119-1132. PubMed ID: 39307151
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of the effects of bitopertin (RG1678) on cardiac repolarization: a thorough corrected QT study in healthy male volunteers.
    Hofmann C, Banken L, Hahn M, Swearingen D, Nagel S, Martin-Facklam M.
    Clin Ther; 2012 Oct 12; 34(10):2061-71. PubMed ID: 22980315
    [Abstract] [Full Text] [Related]

  • 14. Thorough QTc Evaluation and the Safety of Supratherapeutic Doses of Odanacatib in Healthy Subjects.
    McCrea J, Mostoller K, Mahon C, Liu C, Liu F, Zajic S, Panebianco D, Chakravarthy M, Brandquist C, Gutierrez M, Stoch SA.
    Clin Pharmacol Drug Dev; 2019 Oct 12; 8(7):861-870. PubMed ID: 31175709
    [Abstract] [Full Text] [Related]

  • 15. Safety, tolerability, and pharmacokinetics of single oral doses of tofacitinib, a Janus kinase inhibitor, in healthy volunteers.
    Krishnaswami S, Boy M, Chow V, Chan G.
    Clin Pharmacol Drug Dev; 2015 Mar 12; 4(2):83-8. PubMed ID: 27128212
    [Abstract] [Full Text] [Related]

  • 16. A phase 1, randomized study to evaluate safety, tolerability, and pharmacokinetics of GDC-3280, a potential novel anti-fibrotic small molecule, in healthy subjects.
    Cheung D, Fong A, Ding HT, Cabanski CR, Wang J, Chen Y, Bush J, Harris JM, Pan L.
    Pulm Pharmacol Ther; 2021 Aug 12; 69():102051. PubMed ID: 34166834
    [Abstract] [Full Text] [Related]

  • 17. Clinical pharmacology and PK/PD translation of the second-generation Bruton's tyrosine kinase inhibitor, zanubrutinib.
    Tam CS, Ou YC, Trotman J, Opat S.
    Expert Rev Clin Pharmacol; 2021 Nov 12; 14(11):1329-1344. PubMed ID: 34491123
    [Abstract] [Full Text] [Related]

  • 18. Effects of a reactive oxygen species generator, napabucasin (BBI608), on tolerability, safety, pharmacokinetics, and QT/QTc interval in healthy volunteers.
    Noda N, Takagaki T, Yodo Y, Horibuchi Y, Iino S, Matsuki S, Ogama Y, Kakuyama H.
    Pharmacol Res Perspect; 2021 Oct 12; 9(5):e00874. PubMed ID: 34628720
    [Abstract] [Full Text] [Related]

  • 19. Concentration-QTcF Modeling of Icenticaftor from a Randomized, Placebo- and Positive-Controlled Thorough QT Study in Healthy Participants.
    Iyer GR, Darpo B, Xue H, Lecot J, Zack J, Bebrevska L, Weis W, Jones I, Drollmann A.
    Clin Pharmacol Drug Dev; 2024 May 12; 13(5):572-584. PubMed ID: 38284433
    [Abstract] [Full Text] [Related]

  • 20. Population pharmacokinetic and pharmacodynamic modeling of evobrutinib in healthy adult participants.
    Papasouliotis O, Mitchell D, Girard P, Dyroff M.
    Clin Transl Sci; 2022 Dec 12; 15(12):2899-2908. PubMed ID: 36165192
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.